Recurrent Glioma Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting recurrent glioma clinical trials across 2 countries. Studies span Phase 1, Not Applicable, Phase 2. Top locations include New York, New York, United States, Miami, Florida, United States, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Recurrent Glioma Trials at a Glance

8 actively recruiting trials for recurrent glioma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in New York, Miami, and Beijing. Lead sponsors running recurrent glioma studies include Baptist Health South Florida, Kailin Yang, MD, PhD, and Alpha Tau Medical LTD..

Browse recurrent glioma trials by phase

Treatments under study

About Recurrent Glioma Clinical Trials

Looking for clinical trials for Recurrent Glioma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Glioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Glioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Recurrent GliomaRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
National Cancer Institute (NCI)30 enrolled27 locationsNCT05859334
Recruiting
Phase 1Phase 2

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting
Phase 1

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

GlioblastomaGliomaRecurrent Glioblastoma+2 more
Kailin Yang, MD, PhD45 enrolled1 locationNCT07541781
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliomas
Alpha Tau Medical LTD.10 enrolled3 locationsNCT06910306
Recruiting
Not Applicable

PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial

GliomaGlioma, MalignantRecurrent Glioma
Baptist Health South Florida28 enrolled2 locationsNCT06397560
Recruiting
Not Applicable

A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma

GliomaRecurrent Glioma
Mayo Clinic120 enrolled2 locationsNCT07074756
Recruiting
Phase 1

CARv3-TEAM-E T Cells in Glioblastoma

GlioblastomaMalignant GliomaRecurrent Glioblastoma+1 more
Marcela V. Maus, M.D.,Ph.D.21 enrolled1 locationNCT05660369
Recruiting
Phase 1

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Solid TumorRecurrent Glioma
Sichuan Baili Pharmaceutical Co., Ltd.60 enrolled6 locationsNCT04794972